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a b s t r a c t
Aims: Renal denervation is a novel method used to treat patients with resistant hyperten-
sion. Several studies showing the efﬁcacy of this method in blood pressure reduction have
been published. However, there is a lack of data that focused on the technical aspects of the
procedure. The aim of this paper is to present and discuss the technical and safety issues of
the procedure.
Methods and results: 37 patients underwent renal denervation using a Symplicity catheter
between 10/2011 and 8/2013. Number of ablations, procedural time, consumption of contrast
agent and complication rate during hospitalization were recorded. Bilateral denervation was
performed on 35 patients; in 29 of the cases, at least 4 ablations in each renal artery were
done. The average duration of procedure was 57  10 min and the average amount of
contrast agent used was 93  29 ml. During the study, both values were trending downward
as the numbers of procedures increased. We observed minor complications in 9 patients.
None of them were serious and none resulted in patient disability.
Conclusion: Renal denervation is for skilled interventional cardiologist an easy and safe
method with a short learning curve. It may be accompanied by minor complications, not
deteriorating patient health status.
# 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp. z o.o.
All rights reserved.
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achieve optimal blood pressure values, despite the use of
various antihypertensive drugs. This so-called resistant
hypertension, according to the literature, is reported in up
to 10% of the patients with hypertension [2]. These patients
have the highest risk of a serious cardiovascular event [3].
There is growing evidence that resistant hypertension is
accompanied with increased sympathetic activation [4]. Since
the 1950s it has been known that surgical destruction of the
splanchnic sympathetic ﬁbers is effective in lowering high
blood pressure [5]. In the procedure, the renal sympathetic
nerves were not speciﬁcally targeted, although there is no
doubt that they were often surgically interrupted. The method
was abandoned because of serious side effects and increased
mortality. A novel technique for disabling the activity of renal
sympathetic nerves was introduced in 2009 [6]. This method,
called catheter-based renal denervation (RDN), can lower
blood pressure and sympathetic over-activity in patients with
resistant hypertension [7,8]. It is an invasive, endovascular
procedure, in which the destruction of the sympathetic ﬁbers
in the tunica adventitia of renal arteries is achieved using
special catheters. Presently, there are several technical
approaches that can be used for the destruction of perirenal
sympathetic ﬁbers. The most expanded method is a radio-
frequency-based technique developed by Medtronic Inc.,
based on the use of a Symplicity catheter (Medtronic, Ardian
Mountain View, USA). The technique has shown promising
results with blood pressure reduction in patients with
resistant hypertension at 6 [6,7] and even at 24 months [8].
Moreover, it appears that the method is safe and does not
entail serious risks to patients. On the other hand, only
limited data related to the technical limitations and compli-
cations of RDN are currently available. The aim of this paper is
to familiarize professionals with the technique and manage-
ment of patients undergoing RDN. At the same time we
introduce our own safety experiences, technical aspects and
complications we encountered during and after the proce-
dure.
Methods
From 10/2011 to 8/2013 we performed RDN on 37 patients with
resistant hypertension. A diagnosis of resistant hypertension
was based on clinical ofﬁce blood pressure (BP) values higher
than 140/90 mmHg, together with values higher than 130/
80 mmHg during 24-h ambulatory blood pressure monitoring
(ABPM). To be considered as a candidate for the procedure,
patients had to be receiving treatment with a combination of
at least 3 antihypertensive drugs at maximum dosing,
including a diuretic. Prior to enrollment, secondary hyperten-
sion was excluded in all candidate patients and treatment
compliance was conﬁrmed based on drug plasma level
measurements. Exclusion criteria were: renal insufﬁciency
with creatinine higher than 200 mmol/l, pregnancy, a myocar-
dial infarction or stroke within the previous 6 months, a
signiﬁcant stenotic valvular defect, inadequate renal artery
anatomy (i.e. with a length less than 20 mm, or diameter less
than 4 mm), or a severe blood coagulation or aggregation
abnormality. The study was approved by the local ethicscommittee and all participants signed an informed consent to
participate in the project.
Procedural technique
The procedure was performed in a standard catheterization
laboratory equipped with an angiography system Allura Xper
FD20 (Philips, Eindhoven, Netherlands). An invasive cardiolo-
gist, anesthesiologist and three nurses were present during the
procedures. A femoral access site (with a 6F sheath) was used
to reach the arterial system. Aortography and non-selective
arteriography of renal arteries using a pig-tail catheter were
performed as the next step. Depending on the anatomy of the
renal arteries, either a RDND1 (Medtronic, Denver, USA) or an
IMA guiding catheter (Medtronic, Denver, USA) was used. A Y-
connector was attached to the catheter, which was continu-
ously ﬂushed with heparinized saline; additionally, 100 IU/kg
of heparin was administered intravenously. Next a Symplicity
catheter was inserted into the renal artery to perform 4–6
ablations in each renal artery using low-power radiofrequency
energy. Treatments were delivered in a helical fashion within
the renal artery by rotation of the catheter combined with an
approximately 5 mm pullback between ablations. Ablation
time duration was monitored by the generator, which
automatically terminated energy delivery after 120 s with
the maximum applied energy of 8 W. Energy delivery was also
stopped automatically when the temperature of the catheter
tip exceeded the upper limit, or in the event of a sudden
change in the impedance of the surrounding tissue. Stable
contact between the catheter tip and the vessel wall was
required for precise destruction of nerve ﬁbers. The degree of
contact between catheter and vessel wall could be easily
checked visually in the superior and inferior positions. In the
anterior and posterior positions we assess contact based on
impedance values measured at the tip of catheter, which should
not be dramatically different from those in the other positions.
Additionally, impedance values should not change much during
the breathing cycle. A drop in impedance and a rise in
temperature were expected at the end of the ablation; these
changes were used as a predictor of successful treatment. The
procedure concluded with all instruments being removed and
mechanical compression of the puncture site. All RDNs were
done by 2 experienced interventional cardiologists (PW 25, PT
12). The duration time, the dose of contrast agent, blood
pressure and heart rate at the beginning and end of the
procedure, the number of ablations to each renal artery and the
drop in impedance and increase in temperature during each
radiofrequency energy application were recorded for each
procedure. The patient ECG and blood oxygenation were
continuously monitored during the procedure.
Analgosedation
Because of the pain that accompanies RDN, all patients were
given intravenous analgosedation during the procedure. A
combination of ketamine (Calypsol, Gedeon Richter Plc.,
Budapest, Hungary) and propofol (Propofol, Fresenius Kabi
Norge AS, Halden, Norway) was used in 36 patients, while in
one patient, a combination of propofol (Propofol, Fresenius
Kabi Norge AS, Halden, Norway) and sufentanil (Sufenta,
Table 1 – Baseline characteristics of study group.
Patients (n = 37)
Males (n, %) 27, 73
Age in years (mean  SD) 56  15
Diabetes mellitus (n, %) 15, 41
CAD (n, %) 5, 14
Duration of hypertension in years (mean  SD) 15  10
Clinical systolic BP in mmHg (mean  SD) 161  24
Clinical diastolic BP in mmHg (mean  SD) 93  16
ABPM systolic BP in mmHg (mean  SD) 146  13
ABPM diastolic BP in mmHg (mean  SD) 83  9
Number of antihypertensive drugs (mean  SD) 4.95  1.5
BMI in kg/m2 (mean  SD) 32  4
BSA in m2 (mean  SD) 2.1  0.16
Abbreviations: SD – standard deviation, CAD – coronary artery
disease, BP – blood pressure, ABPM – ambulatory blood pressure
monitoring, BMI – body mass index, BSA – body surface area.
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used. After the procedure, patients were transported to the
coronary unit and were usually discharged the next day.
Results
Baseline characteristics of the 37 patients are presented in
Table 1. Bilateral ablation (one or more ablations on both sides)
was performed in 35 patients. The average number of
ablations in the right renal artery was 4.54  1.57 and the
mean number of ablations in the left renal artery was 5.14
 1.16. Twenty-nine (78%) patients had at least 4 ablations
on both sides. A unilateral ablation was performed in 2
patients; in one patient, this was due to tortuous course of the
infrarenal aorta and pelvic arteries, which prevent reaching
the ostium of the right renal artery with the guiding catheter.
The left renal artery required 5 ablations, which were
completed with some degree of difﬁculty (due to guiding
instability). In the second patient, the reason for the unilateral
denervation was due to a discrete ﬁbromuscular dysplasia of
the right renal artery, which was unrecognized on CT;
however, four ablations were successfully performed in the
left renal artery. A total of 3 patients had accessory renal
arteries. Since none of them were wider than 3 mm, ablations
were performed only in the main renal artery.
A total of 358 renal artery ablations were completed. The
mean value of the impedance drop was 14.3  3.5 Ohms and
the mean tissue temperature after energy delivery was 55.2Fig. 1 – Mean duration of the ren 6.3 8C. The average duration of procedure was 57  10 min
and the average amount of contrast agent used was 93  29 ml.
A decreasing trend in both values with rising number of
performed procedures is apparent as a result of operators
increasing experience (Figs. 1 and 2).
In the majority of patients no complications, associated
with the RDN, were observed. In a few patients, there were
some minor complications, although, none required an
extension of the scheduled hospitalization. Phlebitis of the
left forearm, associated with a peripheral line, developed in
one patient. In another patient, asymptomatic bradycardia wasal denervation procedures.
Fig. 2 – Mean consumption of contrast agent in renal denervation procedures.
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treated with a reduction in the dose of beta-blockers. Another
complication involved a laryngospasm that resulted in a short-
term decrease in O2 saturation. The spasm occurred after
analgosedation as well as the procedure had already begun. The
event was managed with orotracheal intubation, which stabi-
lized the patient. Subsequently, we performed a successful
intervention in both renal arteries and the patient was
extubated a few hours later. The patient left the hospital the
next day as planned. Other minor complications (which did not
require prolongation of hospitalization) included renal arteryFig. 3 – (a) Dissection of right renal artery after ablaspasms after application of radiofrequency energy. Spasms
were observed 3 times and were eliminated or reduced through
intra-arterial administration of nitrates. A dissection of the
renal artery occurred in 1 patient. After ablation of the right
renal artery, the lumen of the artery was reduced to about 20%,
which was caused by dissection of the arterial wall with a
concomitant spasm. Nitrates and ﬂuid expansion did not
change the ﬁnding; a 6/12 mm stent was implanted with
optimum results (Fig. 3). The same patient, and the only one in
our study group, also encountered technical problems associ-
ated with the denervation catheter. Because of connectiontion, (b) stent implantation with optimal result.
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ablations on the left renal artery lasted less than 120 seconds
(30 + 15 + 15 s).
There were 2 patients who had complications that
prolonged their hospitalization. One patient had a hematoma
in the right groin and stayed in the hospital for one additional
day. There was no signiﬁcant drop in the blood count and no
transfusion was needed. In the other patient, an arterio-
venous ﬁstula at the access site was observed, and patient
remained in hospital for 2 additional days. The local ﬁnding
regressed spontaneously and did not require any further
intervention.
Discussion
In previous papers it has been repeatedly pointed out that RDN
is a method with potential blood pressure lowering effect in
patients with resistant hypertension [7–9]. So far several
thousand patients with hypertension have been treated using
this method [10] and in some countries the costs of treatment
are covered by public funds. Despite quickly putting the method
into practice, so far, only few data regarding the technical
aspects of performance and complications were published
[7,8,11].
Globally, most patients undergoing the procedure have
been treated with the Symplicity system from Medtronic Inc.
This is also the system used in our department. During the
procedure we used technology and equipment, which has
been previously described [7,8]. As noted above, we were not
able to perform a bilateral renal artery denervation in two
patients. In both cases we were satisﬁed with the effects of
unilateral denervation, although we are aware that the current
views regarding the effect of unilateral denervation on blood
pressure remain controversial [12,13]. One of the prerequisite
for a successful intervention is suitable renal artery anatomy,
with a length greater than 2 cm and a width greater than
4 mm. Therefore, all candidate patients currently undergo a CT
examination of their renal arteries prior to enrollment into the
RDN program in our center.
Another important aspect of the procedure is the number
of ablations performed in each renal artery. We consider it
meaningful to perform a minimum of 4 ablations in each renal
artery, so ablations cover the entire circumference of the
artery. This should ensure sufﬁcient destruction of perirenal
sympathetic nerve ﬁbers. This goal was achieved in 29 (78%) of
the treated patients in our study population. In 6 of the 35
patients undergoing a bilateral procedure we complete a
smaller number of ablations; 3 ablations in one vessel (5
patients) and 2 ablations in one vessel (1 patient). The reason
for the reduced number of ablations involved spasms or
dissection of the renal artery or instability of the guiding
catheter in the ostium of the renal artery. While our
preference was 4–6 ablations per vessel, we do not currently
have enough data regarding an optimal maximum number of
ablations. In a published series of patients, there was no
evidence linking more ablations to a more signiﬁcant decline
in BP.
An important hallmark of an effective ablation is tissue
temperature after application of radiofrequency energy.Previous experiences with arrhythmia ablations in the heart
have shown that a tissue temperature of 50 8C or higher was
necessary for irreversible tissue damage [14]. Along with the
temperature increase, a drop in impedance was also seen. In
the heart, the magnitude of impedance decrease was directly
related to the effectiveness of the heating of the surrounding
tissues during the ablation process [15].
The next aspect to consider is the question of renal artery
stenosis after RDN. Preclinical data on animals have shown
that RDN was safe and did not cause any renal artery stenosis
at the 6-month follow up. Treated arteries had minor changes
in the tunica interna and tunica media of the artery wall. The
main effect of ablation was seen in the periarterial nerve
ﬁbers, which were destroyed and replaced with ﬁbrotic tissue.
Moreover no inﬂammatory changes were present in the
examined samples, which led the authors to believe that the
healing process, after RDN, was completed prior to the time
the samples were taken [16]. Similarly, no renal artery
stenosis was reported in a small subgroup of patients
examined using magnetic resonance imaging (MRI) at the
6-month follow-up of the Symplicity HTN-1 trial [7]. Reports
from the extended Symplicity HTN-1 study population
showed one progression of a pre-existing renal artery stenosis
at a location different from the ablation site [9]. Nonetheless,
the subgroup of patients was examined using only duplex
ultrasound, which may not be the best method for detecting
renal artery stenosis compared to computer tomography or
MRI [17]. Contrary to that, 2 cases of renal artery stenosis after
RDN were published in last year. Both occurred 5–6 months
after successful RDN and led to a re-elevation of previously
depressed blood pressure. Stents implantations were carried
out; the authors noted the lack of data related to long term
safety after RDN [18,19]. Until there is more deﬁnitive data on
long-term safety, it is reasonable to avoid excessive ablations
in the renal arteries. Only one patient in our center had more
than 6 ablations in 1 artery (8 ablations in the right and 10
ablations in the left renal artery), the majority of patients had
4–6 ablations per vessel.
According to current data, RDN is associated with a low
incidence, of mostly, minor complications. Among the partici-
pants in the Symplicity HTN-1 study, complications were
reported in about 5% of patients [7]. These were mainly less
serious complications such as post procedural ﬂank pain or
pseudoaneurysms at the puncture site. Only one patient
suffered a renal artery dissection during catheter manipulation
inside the artery. The situation was resolved with the
implantation of a stent [7]. There was also one renal artery
dissection in a group of 49 patients participating in the
Symplicity HTN-2 study. In this case the dissection was caused
by manipulation of the guiding catheter in the ostium of the
renal artery. As with the ﬁrst case, the problem was resolved
with the implantation of a stent [8]. Other reported complica-
tions included: pseudoaneurysm of the femoral artery, urinary
tract infections, back pain and hypotension, which resolved
after reduction of antihypertensive therapy and ﬂuid replace-
ment.
There is not much additional information on the safety of
RDN available. In one published paper, the authors described
one occurrence of a severe renal artery spasm and 1 case of
cardiorespiratory depression from a sample of 53 RDN
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ratory depression led to an interruption of the procedure [11].
We observed a similar complication in one of our patients;
however, we were able to continue the procedure without
interruption. We also experienced several cases of vasos-
pasms, which responded to nitrates, although in some
patients the vasospasms led to a reduction in the number of
ablations performed. Our most serious complication was a
renal artery dissection, which occurred after application of
radiofrequency energy. As with the previously mentioned
cases, the dissection was managed with stent implantation,
and the patient was discharged from the hospital, as
scheduled, on the following day. It seems that during the
procedure, it is necessary to count with a certain low risk of
artery dissection. It can be caused by mechanical forces or
radiofrequency energy application. However, as shown in a
study with optical coherence tomography after RDN, small, by
angiography unrecognized dissections, can be present more
often [20].
Initial success of the Metronic Symplicity device, has
inspired many other companies to develop their own methods
of RDN. Most of them are based on the application of
radiofrequency energy [20–22]. Potential advantages include
shorter energy delivery times [22] or complete denervation in a
single treatment per vessel [21]. Another new RDN technique
uses ultrasound [23] and moreover pharmacological RDN
methods are now under investigation. Successful destruction
of perirenal nerve ﬁbers in animal models has been archived
with application of guanethidine [24] or ethanol [25].
In conclusion, renal denervation might be a promising non-
pharmacological, device-based, method for treatment of
hypertension. Our experiences suggest that the method is
safe in the hands of skilled interventional cardiologist and the
procedure has a short learning curve. However, studies
focused on long-term safety, especially development of late-
onset renal artery stenosis, are still missing. The fact that
currently published data, showed discrepancies in observed BP
reduction after RDN [26–28], only strengthens the need of long-
term safety and long-term effectiveness studies before RDN
becomes a routine method for treatment of resistant hyper-
tension.
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Appendix
During the review phase of this manuscript Medtronic
announced preliminarily, that the largest randomized study,
SYMPLICITY-HTN-3, conﬁrmed the safety, but failed to demon-
strate clinical effectiveness of catheter-based renal denervation
[30]. Thus, the question arises, whether this result is a failure of
[1] the study design, [2] the speciﬁc ﬁrst generation Symplicity
catheter or [3] the overall concept of catheter-based renal
denervation.
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